Is Sorrento Therapeutics Stock a Buy?

Zhiyuan Sun, The Motley Fool
·4-min read
Is Sorrento Therapeutics Stock a Buy?
Is Sorrento Therapeutics Stock a Buy?

Back in May, Sorrento Therapeutics (NASDAQ: SRNE) captivated investor attention after it claimed the discovery of an antibody that can provide "100% inhibition" against COVID-19. In fact, the company's senior vice president, Dr. Mark Brunswick, made the following statement in an interview by Fox News: "So, if we were approved [by the U.S. Food and Drug Administration (FDA)] today, everyone who gets that antibody can go back to work and have no fear of catching COVID-19." If we have the neutralizing antibody in your body, you don't need the social distancing.